KDNY Chinook Therapeutics Inc.

$22.65 $2.39 (11.80%)
Overall

KDNY Stock Analysis Overview

What this means: Chinook Therapeutics Inc. (KDNY) gets a very positive evaluation from InvestorsObserver's ranking system. An Overall Rank of 83 means that our comprehensive methodology rates Chinook Therapeutics Inc. above 83% of stocks.

Who this matters to: Overall Ranking is a comprehensive evaluation. It considers technical and fundamental factors and is a good starting point for evaluating a stock.

View Sample Report
Fundamental PREMIUM

KDNY Fundamental Analysis

Who this matters to: The Fundamental Ranking considers the health of the underlying company. It is best used by longer-term buy-and-hold investors.

Upgrade to Premium to unlock Fundamental Ranking

Short-Term Technical PREMIUM

KDNY Short-Term Technical Analysis

Who this matters to: The Short-Term Technical Ranking evaluates a stock’s trading over the past month. This is most useful for short- to medium-term stock and option traders.

Upgrade to Premium to unlock Short-Term Technical Ranking

Long-Term Technical PREMIUM

KDNY Long-Term Technical Analysis

Who this matters to: The Long-Term Technical Ranking is a good gauge of how a stock has traded over the past several months. This is useful for medium to long-term stock and option traders.

Upgrade to Premium to unlock Long-Term Technical Ranking

Analyst Ranking PREMIUM

KDNY Analyst Ranking

Who this matters to: Analyst Ranking shows you which stocks Wall Street analysts like the most. Since analysts build valuation models, this is most useful for medium to long-term investors who are interested in a valuation-based approach.

Upgrade to Premium to unlock Analyst Ranking Analysis

Valuation PREMIUM

KDNY Valuation Ranking Analysis

Who this matters to: Valuation Ranking is most-useful for value-focused investors who plan to hold a stock for the long term.

Upgrade to Premium to unlock Valuation Ranking

Stock Sentiment PREMIUM

KDNY Stock Sentiment Analysis

Who this matters to: Sentiment Rank looks at the past five trading days. This is our shortest-term evaluation and is best used by people with a very short horizon.

Upgrade to Premium to unlock Stock Sentiment Ranking

KDNY Stock Analysis Overview

What this means: Chinook Therapeutics Inc. (KDNY) gets a very positive evaluation from InvestorsObserver's ranking system. An Overall Rank of 83 means that our comprehensive methodology rates Chinook Therapeutics Inc. above 83% of stocks.

Who this matters to: Overall Ranking is a comprehensive evaluation. It considers technical and fundamental factors and is a good starting point for evaluating a stock.

Create a FREE account to see full KDNY report

KDNY Fundamental Analysis

Who this matters to: The Fundamental Ranking considers the health of the underlying company. It is best used by longer-term buy-and-hold investors.

Upgrade to Premium to unlock Fundamental Ranking

KDNY Short-Term Technical Analysis

Who this matters to: The Short-Term Technical Ranking evaluates a stock’s trading over the past month. This is most useful for short- to medium-term stock and option traders.

Upgrade to Premium to unlock Short-Term Technical Ranking

KDNY Long-Term Technical Analysis

Who this matters to: The Long-Term Technical Ranking is a good gauge of how a stock has traded over the past several months. This is useful for medium to long-term stock and option traders.

Upgrade to Premium to unlock Long-Term Technical Ranking

KDNY Analyst Ranking

Who this matters to: Analyst Ranking shows you which stocks Wall Street analysts like the most. Since analysts build valuation models, this is most useful for medium to long-term investors who are interested in a valuation-based approach.

Upgrade to Premium to unlock Analyst Ranking Analysis

KDNY Valuation Ranking Analysis

Who this matters to: Valuation Ranking is most-useful for value-focused investors who plan to hold a stock for the long term.

Upgrade to Premium to unlock Valuation Ranking

KDNY Stock Sentiment Analysis

Who this matters to: Sentiment Rank looks at the past five trading days. This is our shortest-term evaluation and is best used by people with a very short horizon.

Upgrade to Premium to unlock Stock Sentiment Ranking

Chinook Therapeutics Inc. (KDNY) Analyst Forecast

KDNY Price, Volume, Earnings, and Dividend Date

  • Last Price $22.65
  • Previous Close $20.26
  • Change $2.39
  • Open $20.46
  • Volume 998,254
  • Avg. Volume (100-day) 535,849
  • Market Cap 1,295,436,961
  • Days Range 20.4 - 22.805
  • 52-week Range 11.16 - 23.86
  • Dividend Yield
  • Ex. Dividend Date
  • P-E
  • EPS
  • Earnings Date 02/08/23
  • Sector Healthcare
  • Industry Biotechnology
  • Avg. Analyst Rec. Premium
  • Beta 0.521
  • PEG Ratio

Chinook Therapeutics Inc. (KDNY) Company Description

Chinook Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing precision medicines for kidney diseases. The products of the company are focused on rare, severe chronic kidney disorders.

Chinook Therapeutics Inc. (KDNY) Stock Chart

My Watchlists

Follow Your Favorite Stocks